Alpine Woods Capital Investors LLC Takes $558,000 Position in Humana Inc. (NYSE:HUM)

Alpine Woods Capital Investors LLC acquired a new stake in Humana Inc. (NYSE:HUM - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 2,200 shares of the insurance provider's stock, valued at approximately $558,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Madison Investment Advisors LLC acquired a new position in Humana in the 4th quarter valued at approximately $2,038,000. LFA Lugano Financial Advisors SA increased its position in Humana by 56.3% in the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock valued at $32,000 after acquiring an additional 45 shares during the period. Skandinaviska Enskilda Banken AB publ increased its position in Humana by 0.3% in the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 24,097 shares of the insurance provider's stock valued at $6,127,000 after acquiring an additional 84 shares during the period. Achmea Investment Management B.V. increased its position in Humana by 6.7% in the 4th quarter. Achmea Investment Management B.V. now owns 10,330 shares of the insurance provider's stock valued at $2,621,000 after acquiring an additional 651 shares during the period. Finally, Vestcor Inc increased its position in Humana by 146.3% in the 4th quarter. Vestcor Inc now owns 5,914 shares of the insurance provider's stock valued at $1,500,000 after acquiring an additional 3,513 shares during the period. Institutional investors own 92.38% of the company's stock.

Insider Buying and Selling at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the business's stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.32% of the company's stock.

Remove Ads

Humana Stock Up 2.1 %

Shares of HUM traded up $5.45 during trading hours on Tuesday, reaching $269.86. 1,632,536 shares of the stock traded hands, compared to its average volume of 1,713,453. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The stock has a fifty day simple moving average of $271.39 and a 200 day simple moving average of $278.89. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $406.46. The company has a market cap of $32.57 billion, a price-to-earnings ratio of 27.12, a PEG ratio of 2.05 and a beta of 0.57.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating analysts' consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. On average, equities analysts forecast that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.31%. The ex-dividend date of this dividend is Friday, March 28th. Humana's payout ratio is 35.58%.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on HUM. Piper Sandler upped their price target on shares of Humana from $270.00 to $288.00 and gave the company a "neutral" rating in a research report on Wednesday, January 15th. JPMorgan Chase & Co. decreased their price objective on shares of Humana from $257.00 to $256.00 and set a "neutral" rating for the company in a research report on Tuesday, February 18th. Barclays increased their price objective on shares of Humana from $255.00 to $270.00 and gave the stock an "equal weight" rating in a research report on Thursday, February 13th. Cantor Fitzgerald reiterated a "neutral" rating and set a $290.00 price objective on shares of Humana in a research report on Wednesday, February 12th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $283.00 price objective on shares of Humana in a research report on Wednesday, February 12th. Nineteen research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Humana currently has a consensus rating of "Hold" and a consensus price target of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.